

ASSOCIATION OF COMMUNITY CANCER CENTERS


UNDERSTANDING THE INTEGRATION OF PATHOLOGY WITH THE CANCER CARE TEAM SURVEY HIGHLIGHTS

In an era of precision medicine and rapidly-advancing cancer therapeutics, the role of pathology in the diagnosis and management of cancer is evolving. Starting at the point of cancer diagnosis, pathologists provide expert interpretation and may recommend biomarker testing to guide treatment decisions. Pathologists may also play a role in determining clinical trial eligibility or recommending treatment options, especially for patients who do not respond to the standard of care. Recent advances in targeted therapies, molecular

biology, and immuno-oncology necessitate a closer integration of pathology with the multidisciplinary cancer care team.


The Association of Community Cancer Centers (ACCC), along with its partners, the Association for Molecular Pathology (AMP), American Society for Clinical Pathology (ASCP), and College of American Pathologists (CAP) conducted this survey in 2018 to better understand the current landscape of how pathology is integrated with the cancer care team.

Who took our survey?




Note: Other = navigators, social workers, tumor registrars, research coordinators, genetic counselors
N=659

Which best describes your cancer program?



N=659


On average, how many new cancers are diagnosed at your program each year?



N=318


PATHOLOGY ROLES AND TESTING WORKFLOWS

Do your pathologists focus on the diagnosis of specific types of cancers?




N=437

Are pathologists authorized to order cancer biomarker tests?



N=384


What patient health records can your pathologists directly access?




N=513

How does your pathology lab perform and interpret the following cancer biomarker tests?


Perform and Interpret Testing In-House



Send Samples Out for Testing and Interpretation




Combined Use of In-House and Outside Lab Testing and Interpretation



N=385


Outside Lab Turnaround Time

When tissue samples go to an outside lab for testing, what is the turn around time?




N=272

Does your cancer program have dedicated experts in molecular pathology and/or cancer genetics and genomics?



Which cancers have "reflex" biomarker testing protocols?




Uptake of Next Generation Sequencing (NGS) Testing

67% of respondents report use of NGS for solid tumors and/or hematologic malignancies, but are evenly split between occasional NGS testing (34%) and routine NGS ordering for several types of tumors (33%). Another 19% routinely order NGS for one or two tumor types, and 14% report rarely using NGS testing.


N=249

Describe your clinicians' current use of liquid biopsy (circulating tumor DNA) testing.



N=205


Top challenges/barriers to biomarker testing at your program?



N=355

PATHOLOGY AND TREATMENT RECOMMENDATIONS/TUMOR BOARDS

Which type(s) of tumor boards or case conferences are regularly held at your cancer program?




N=250

76% of respondents report that pathologists **attend** more than 75% of tumor boards, either in person or virtually. Only 3% report that pathologists are **not attending** these meetings.


N=250

How often do your pathologists attend hospital cancer committee meetings?




N=202

Our pathologists engage in collaborative discussions with these clinicians prior to making a diagnosis of cancer.



N=330

Do your pathologists recommend clinical treatment options for patients with cancer?



N=331

Biggest barriers and challenges to the successful integration of pathology into your cancer care team.

Lack of time
ATTITUDES COMMUNICATION
physical location
 REIMBURSEMENT

N=170



Association of Community Cancer Centers

1801 Research Boulevard, Suite 400
Rockville, MD 20850
301.984.9496
acc-cancer.org

A publication from the ACCC education program, "Understanding the Integration of Pathology with the Cancer Care Team." Learn more at acc-cancer.org/pathology.

The **Association of Community Cancer Centers (ACCC)** is the leading education and advocacy organization for the multidisciplinary cancer team. ACCC is a powerful network of 24,000 cancer professionals from 2,100 hospitals and practices nationwide. ACCC is recognized as the premier provider of resources for the entire oncology care team. For more information visit acc-cancer.org or call 301.984.9496. Follow us on Facebook, Twitter, and LinkedIn, and read our blog, ACCCBuzz.

© 2018. Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.

This publication is a benefit of ACCC membership.

This survey was promoted through a collaboration between:



This education program is made possible through our supporters:

